Video

Dr. Basu-Mallick on Ongoing Research With ctDNA in CRC

Atrayee Basu-Mallick, MD, discusses the role of circulating tumor DNA in patients with colorectal cancer.

Atrayee Basu-Mallick, MD, a medical oncologist at Sidney Kimmel Cancer Center and clinical assistant professor at Thomas Jefferson University, discusses the role of circulating tumor DNA (ctDNA) in patients with colorectal cancer (CRC).

In the future, the escalation or de-escalation of care could be based on ctDNA, as it appears to be a reliable prognostic biomarker, Basu-Mallick says. Additionally, ctDNA could help to examine new agents in this patient population by achieving quicker end points in clinical trials, Basu-Mallick notes.

Currently, the ongoing phase 2/3 NRG-GI005 or COBRA trial (NCT04068103) is examining treatment escalation based on ctDNA for patients with stage IIA disease who are not eligible for adjuvant therapy, Basu-Mallick explains. Additionally, the ongoing NRG-GI008 trial (NCT04120701) will enroll low-risk patients with stage III disease and evaluate both therapy escalation for those who are ctDNA positive, and de-escalation for those who are ctDNA negative, Basu-Mallick concludes.

Related Videos
Aparna Parikh, MD
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Kimmie Ng, MD, MPH
Cathy Eng, MD, FACP, FASCO
Kimmie Ng, MD, MPH
Kimmie Ng, MD, MPH
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Richard Kim, MD
Arvind N. Dasari, MD, MS